<--- Back to Details
First PageDocument Content
Medicine / Clinical medicine / Cancer / Antineoplastic drugs / Cancer treatments / Oncology / Breast cancer / Surgical oncology / Chemotherapy / Hematopoietic stem cell transplantation / Docetaxel / Metastatic breast cancer
Date: 2010-02-19 06:19:37
Medicine
Clinical medicine
Cancer
Antineoplastic drugs
Cancer treatments
Oncology
Breast cancer
Surgical oncology
Chemotherapy
Hematopoietic stem cell transplantation
Docetaxel
Metastatic breast cancer

Bone Marrow Transplantation, 205–210 & 2003 Nature Publishing Group All rights reserved $25.00 www.nature.com/bmt Economic analysis

Add to Reading List

Source URL: www.nature.com

Download Document from Source Website

File Size: 118,89 KB

Share Document on Facebook

Similar Documents

Edorium J Disabil Rehabil 2015;1:9–11. www.edoriumjournals.com/ej/dr Letter to Editors	  Massoni et al. 

Edorium J Disabil Rehabil 2015;1:9–11. www.edoriumjournals.com/ej/dr Letter to Editors Massoni et al. 

DocID: 1ru4d - View Document

Original Research  Maternal and Neonatal Outcomes of Dose-Dense Chemotherapy for Breast Cancer in Pregnancy Elyce Cardonick,

Original Research Maternal and Neonatal Outcomes of Dose-Dense Chemotherapy for Breast Cancer in Pregnancy Elyce Cardonick,

DocID: 1rr4j - View Document

EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

DocID: 1rhhk - View Document

When Patients Win, We All Win™  Provectus Biopharmaceuticals, Inc Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigation

When Patients Win, We All Win™ Provectus Biopharmaceuticals, Inc Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigation

DocID: 1rgN5 - View Document

Intralesional therapy is a possible treatment option for patients with metastatic melanoma due to its good local response and tolerable adverse-event profile.  Photo courtesy of Dina Potter. Sunny Tree. 48

Intralesional therapy is a possible treatment option for patients with metastatic melanoma due to its good local response and tolerable adverse-event profile. Photo courtesy of Dina Potter. Sunny Tree. 48" × 60".

DocID: 1rePY - View Document